Adia Med Inc.

Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing

2026-08-11 08:00:00

Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m.

Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration Opportunities

2026-08-05 16:30:00

Winter Park, Florida--(Newsfile Corp. - August 5, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced that it will host a private dinner for physicians and investors on Wednesday, August 5, 2026, at 7:00 PM at Christner's Steakhouse. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/308113_adia_med_x_banner.jpg The dinner will provide an overview of Adia Med's current clinical studies, including its ongoing Autism Spectrum Disorder research study and other regenerative medicine initiatives.

Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study

2026-07-29 06:00:00

Next Cohort of 30 Children to Begin a New Phase 1 Treatment Group on October 1, 2026, as Successive Enrollment Continues Every Three Months Winter Park, Florida--(Newsfile Corp. - July 29, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced two distinct milestones in its Autism Spectrum Disorder (ASD) clinical research study (ClinicalTrials.gov Identifier: NCT07304440): the completion of Phase 1 treatment for the study's first cohort of children, and the formal launch of Phase 2 of the study. Separately, the company confirmed that a new cohort of 30 children will begin its own Phase 1 treatment on October 1, 2026, as part of the study's ongoing, staggered enrollment schedule.

Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

2026-07-15 09:30:00

New Platform Now Live, Featuring Expanded Sections on Clinical Studies, Stem Cell Therapies, Aesthetics, Media, Podcasts, Case Studies, and Investor Resources Winter Park, Florida--(Newsfile Corp. - July 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a clinical-stage regenerative medicine company, today announced the launch of its redesigned corporate website. The redesigned website is now live, with the project still in progress and active changes and improvements currently being made.

Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ

2026-07-13 09:00:00

Winter Park, Florida--(Newsfile Corp. - July 13, 2026) - Adia Med Inc. (OTCQB: ADIA) (formerly Adia Nutrition Inc.), focused on regenerative medicine, stem cell therapies, and biologics, today highlighted its rapid advancement and major milestones achieved since the January 2024 leadership transition. To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10520/304722_adia_med_x_banner.jpg On January 22, 2024, Larry Powalisz assumed the role of CEO and Director following a change of control, with Rebecca Miller appointed as CFO.

Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review

2026-07-09 08:00:00

Name change to appear on Daily List today following expedited review; trading begins tomorrow Winter Park, Florida--(Newsfile Corp. - July 9, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA) announced today that FINRA has processed its corporate name change to Adia Med Inc. on an expedited timeline. The name change will be reflected on the FINRA Daily List today, with trading under the new name expected to begin tomorrow, Friday, July 10, 2026, on the OTC Markets.

Adia Nutrition Inc. Enters FINRA Home Stretch for Corporate Name Change to Adia Med Inc.

2026-07-07 10:19:00

Company Believes All Requirements Satisfied; Approval Expected in the Coming Weeks Winter Park, Florida--(Newsfile Corp. - July 7, 2026) - Adia Nutrition Inc. (OTCQB: ADIA) today announced it has entered the final stage of its corporate name change application from Adia Nutrition Inc. to Adia Med Inc. After several months of review by the Financial Industry Regulatory Authority (FINRA), including three rounds of comments and the submission of detailed supporting documentation, the Company believes it has now met all outstanding requirements. FINRA approval is anticipated within the coming weeks.

Adia Med Finds Another Unicorn

2026-06-30 12:49:00

CEO Larry Powalisz Spotlights Dr. Lyday, a Leading Stem Cell Champion, in New Podcast. Winter Park, Florida--(Newsfile Corp. - June 30, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine and stem cell therapies company, today announced that CEO Larry Powalisz recently sat down for a podcast interview with Dr. Lyday, a physician recognized as a champion for stem cell-based treatments.